Phage Therapy Market Report with Forecast 2026 to 2035
Segmentation of Phage Therapy Market :
Phage Therapy Market, by Development Stage-
- Preclinical
- Phase I / II
- Phase III
- Compassionate / Expanded Access Use
- Approved / Commercial (Future launches post-2027)
Phage Therapy Market, Based on Route of Administration-
- Topical / Dermal
- Oral
- Injectable / Intravenous
- Inhalation / Nebulized
- Local Instillation (e.g., bladder, sinus, wound cavity)
Phage Therapy Market, Based on By Product Type / Mechanism-
- Monophage
- Phage Cocktails
- Engineered / Recombinant Phages
- Phage-Derived Enzymes
- Combination Products
Phage Therapy Market, Based on By Target Indication-
- Skin & Wound Infections
- Respiratory Tract Infections
- Urinary Tract Infections (UTI)
- Bone & Joint / Implant-Associated Infections
- Bloodstream / Sepsis
- Gastrointestinal Infections
- Biofilm-related Chronic Infections
Phage Therapy Market, Based on By Target Pathogen-
- Gram-Negative Bacteria
- Gram-Positive Bacteria
- Mixed / Other Pathogens
Phage Therapy Market, Based on Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Phage Therapy Market Snapshot
Chapter 4. Global Phage Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis
5.1. By Route of Administration, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
5.2.1. Oral
5.2.2. Topical
5.2.3. Rectal Route
5.2.4. Intravenous Route
5.2.5. Inhalation
Chapter 6. Market Segmentation 1: By Product Type, Estimates & Trend Analysis
6.1. By Product Type, & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product Type:
6.2.1. Monophage
6.2.2. Phage Cocktails
6.2.3. Combination Products
6.2.4. Phage-Derived Enzymes
Chapter 7. Market Segmentation 1: By Development Stage, Estimates & Trend Analysis
7.1. By Development Stage, & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Development Stage:
7.2.1. Preclinical Topical
7.2.2. Phase I / II Intravenous Route
7.2.3. Compassionate
7.2.4. Phase III
Chapter 8. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
8.1. By Distribution Channel & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Market Segmentation 3: By Target Pathogen Estimates & Trend Analysis
9.1. By Target Pathogen & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Target Pathogen:
9.2.1. Gram-Negative Bacteria
9.2.2. Gram-Positive Bacteria
9.2.3. Mixed / Other Pathogens
Chapter 10. Market Segmentation 3: By Target Indication Estimates & Trend Analysis
10.1. By Target Indication & Market Share, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Target Indication:
10.2.1. Urinary Tract Infections
10.2.2. Chronic Otitis
10.2.3. Dental Extraction
10.2.4. Chronic Ulcerative Colitis
10.2.5. Bone Infection
10.2.6. Wound and Skin Infections
10.2.7. Cystic Fibrosis
10.2.8. Other Disease Indications
Chapter 11. Phage Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Phage Therapy Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
11.1.2. North America Phage Therapy Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
11.1.3. North America Phage Therapy Market revenue (US$ Million) estimates and forecasts By Targeted Bacteria, 2021-2034
11.1.4. North America Phage Therapy Market revenue (US$ Million) estimates and forecasts By Disease Indication, 2021-2034
11.1.5. North America Phage Therapy Market revenue (US$ Million) estimates and forecasts by Development Stage, 2021-2034
11.1.6. North America Phage Therapy Market revenue (US$ Million) estimates and forecasts by Product Type, 2021-2034
11.2. Europe
11.2.1. Europe Phage Therapy Market revenue (US$ Million) By Route of Administration, 2021-2034
11.2.2. Europe Phage Therapy Market revenue (US$ Million) By Distribution Channel, 2021-2034
11.2.3. Europe Phage Therapy Market revenue (US$ Million) estimates and forecasts By Targeted Bacteria, 2021-2034
11.2.4. Europe Phage Therapy Market revenue (US$ Million) estimates and forecasts By Disease Indication, 2021-2034
11.2.5. Europe Phage Therapy Market revenue (US$ Million) estimates and forecasts by Development Stage, 2021-2034
11.2.6. Europe Phage Therapy Market revenue (US$ Million) estimates and forecasts by Product Type, 2021-2034
11.3. Asia Pacific
11.3.1. Asia Pacific Phage Therapy Market revenue (US$ Million) By Route of Administration, 2021-2034
11.3.2. Asia Pacific Phage Therapy Market revenue (US$ Million) By Distribution Channel, 2021-2034
11.3.3. Asia Pacific Phage Therapy Market revenue (US$ Million) estimates and forecasts By Targeted Bacteria, 2021-2034
11.3.4. Asia Pacific Phage Therapy Market revenue (US$ Million) estimates and forecasts By Disease Indication, 2021-2034
11.3.5. Asia Pacific Phage Therapy Market revenue (US$ Million) estimates and forecasts by Development Stage, 2021-2034
11.3.6. Asia Pacific Phage Therapy Market revenue (US$ Million) estimates and forecasts by Product Type, 2021-2034
11.4. Latin America
11.4.1. Latin America Phage Therapy Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
11.4.2. Latin America Phage Therapy Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2021-2034
11.4.3. Latin America Phage Therapy Market revenue (US$ Million) estimates and forecasts By Targeted Bacteria, 2021-2034
11.4.4. Latin America Phage Therapy Market revenue (US$ Million) estimates and forecasts By Disease Indication, 2021-2034
11.4.5. Latin America Phage Therapy Market revenue (US$ Million) estimates and forecasts by Development Stage, 2021-2034
11.4.6. Latin America Phage Therapy Market revenue (US$ Million) estimates and forecasts by Product Type, 2021-2034
11.5. Middle East & Africa
11.5.1. Middle East & Africa Phage Therapy Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
11.5.2. Middle East & Africa Phage Therapy Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2021-2034
11.5.3. Middle East & Africa Phage Therapy Market revenue (US$ Million) estimates and forecasts By Targeted Bacteria, 2021-2034
11.5.4. Middle East & Africa Phage Therapy Market revenue (US$ Million) estimates and forecasts By Disease Indication, 2021-2034
11.5.5. Middle East & Africa Therapy Market revenue (US$ Million) estimates and forecasts by Development Stage, 2021-2034
11.5.6. Middle East & Africa Phage Therapy Market revenue (US$ Million) estimates and forecasts by Product Type, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Adaptive Phage Therapeutics
12.2.2. Armata Pharmaceuticals
12.2.3. BiomX (MBcure Ltd.)
12.2.4. Locus Biosciences
12.2.5. Intralytix, Inc.
12.2.6. Pherecydes Pharma
12.2.7. PhagoMed Biopharma
12.2.8. PHAXIAM Therapeutics
12.2.9. Technophage (TechnoPhage S.A.)
12.2.10. Phage International
12.2.11. Eliava BioPreparations
12.2.12. Phagelux
12.2.13. Nextbiotics
12.2.14. Micreos Human Health
12.2.15. ContraFect
12.2.16. EnBiotix
12.2.17. Proteon Pharmaceuticals
12.2.18. PhagePro, PBC
12.2.19. SNIPR Biome
12.2.20. Eligo Bioscience
12.2.21. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Phage Therapy Market is expected to grow at an 21.60% CAGR during the forecast period for 2026 to 2035.
Armata Pharmaceuticals, Inc., BiomX (MBcure Ltd.), Eligo Bioscience, Intralytix, Inc., iNtODEWorld, Locus Biosciences, MicroPhage, Inc., TechnoPhage, Microgen Russia, Aumed, Aziya immunopreparat LLC, Sensei Biotherapeutics, Eliava BioPreparations, Nextbiotics, PhagePro, Nexabiome and Other Prominent Players
Phage Therapy Market is segmented in Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Route of Administration (Oral, Topical, Rectal Route, Intravenous Route), by Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, Other Bacteria), by Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, Other Disease Indications), By Development Stage, By Product Type, By Target Indication, By Target Pathogen,
North America region is leading the Phage Therapy Market.